rationale and objective: the goal of this study was to determine the clinical efficacy and safety of drug-eluting bead (deb) transarterial chemoembolization (tace) in combination with apatinib administration in patients with advanced hepatocellular carcinoma (hcc).
materials and methods: from december 2015 to may 2017, a total of 32 patients with advanced hcc treated with deb-tace combined with apatinib were consecutively enrolled in this study. the treatment response and laboratory outcomes were assessed at the first- and third month after deb-tace therapy. overall survival, progression-free survival, and adverse events were also analyzed and assessed.
材料和方法：自2015年12月至2017年5月，连续纳入32例晚期hcc患者，采用deb-tace （callispheres 300-500μm 载吡柔比星60-80 mg）联合阿帕替尼进行治疗。在deb-tace治疗后的第1个月和第3个月评估治疗反应和实验室结果。对总体生存、无进展生存期和不良事件亦进行分析和评估。
results: the objective response rate and disease control rate were 62.5% and 96.9% at the first month after treatment, respectively. at the third month after the first therapy, a slightly higher objective response rate (68.8%) and lower disease control rate (90.6%) were achieved. there were no differences in the levels of aspartate aminotransferase, alanine aminotransferase, serum albumin, or total bilirubin at m1 or m3 compared to m0 (all p> 0.05). the median progression-free survival was 9.5 months (95% confidence interval, 8.1-10.9 months), and the median overall survival was 22.0 months (95% confidence interval, 20.2-23.9 months). among the 32 patients, 2 had hypertension and 1 had grade 3 diarrhea; the rest of the patients had mild to moderate adverse reactions that were acceptable, and no serious adverse reactions occurred.
conclusion: deb-tace combined with apatinib is a safe and promising treatment approach for patients with advanced hcc.